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Summary 
Drugs with potential to lower the seizure threshold are numerous and diverse. Whether they contribute 
to clinically overt seizures depends on the dosage in which they are taken, the time-course of their 
effects, and the susceptibility of the patient. Crucially, however, their contribution to seizure risk is 
potentially modifiable. 
Seizures and the seizure threshold 
Terminology 
A seizure is the clinical manifestation of abnormal, excessive or synchronous neuronal firing in the brain.1 
The clinical features of seizures may include abnormalities of consciousness, movement, sensation, 
behaviour and autonomic function. Epilepsy is the enduring tendency to experience seizures.  
The seizure threshold describes the minimum intensity of a stimulus required to induce a seizure. It is 
clinically evident in the context of electroconvulsive therapy, but is otherwise primarily an experimental 
phenomenon, in which seizures are induced by electrical or chemical stimuli (e.g. with 
pentylenetetrazole). It is often evaluated during drug development to quantify the extent to which a drug 
prevents seizures (if this is the intended therapeutic effect) or induces them (as an unwanted effect). As a 
broader concept, it is useful in clinical practice as a framework to help understand the complex interplay 
between the patient, their medicines, and their risk of seizures. 
Pathophysiology and pharmacology 
Seizures occur when there is an excess of excitatory activity relative to inhibitory activity. Glutamate and 
gamma-aminobutyric acid (GABA) are, respectively, the principle excitatory and inhibitory 
neurotransmitters in the central nervous system (CNS). Glutamate acts via N-methyl-D-aspartate 
(NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and kainite receptors to 
cause an influx of sodium and calcium ions, favouring depolarisation. GABA acts primarily through GABAA 
receptors to cause an influx of chloride ions, inducing hyperpolarisation. The mechanisms of action of 
antiepileptic drugs are not universally understood, but include inference with sodium (e.g. phenytoin, 
carbamazepine, lamotrigine) and calcium channels (e.g. ethosuxamide); enhancing the effects of GABA 
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(e.g. benzodiazepines); antagonising glutamate at AMPA receptors (e.g. perampanel); and a combination 
of these effects (e.g. valproate). Drugs with the opposite effects may induce seizures. 
The propensity of a drug to induce seizures depends on its effects on neurotransmission and their time-
course (e.g. whether it increases seizure risk during use or on withdrawal), the concentration of drug 
reaching the brain, and the susceptibility of the individual patient. Susceptibility factors include previous 
seizures, structural or functional brain abnormalities, and concurrent drug use. In the face of such 
complexity, it is rare that seizures can be ascribed primarily to the effects of a drug (i.e. ‘drug-induced 
seizures’). Commonly, however, drugs contribute to a shift in excitatory/inhibitory balance which, in that 
individual at that time, leads to a seizure. In this respect, it is generally more helpful to regard such drugs 
as having lowered the seizure threshold, rather than having incited seizures per se. 
Many drugs have indirect effects on the seizure threshold, for example by inducing hypoglycaemia, 
electrolyte disturbances or respiratory depression, or by interacting with antiepileptic therapy. However, 
this review will concentrate on drugs that lower the seizure threshold via direct effects in the brain. 
Specific drugs 
Antimicrobials 
Beta-lactams 
Beta-lactam antibiotics, including penicillins, cephalosporins and carbapenems, interact with the GABAA 
receptor to interfere with the inhibitory effects of GABA in a concentration-dependent manner.2 
Correspondingly, they have dose-dependent effects on the seizure threshold.3,4 However, the CNS 
penetration of penicillins and cephalosporins is relatively low.5 As such, most reports of seizures 
associated with these agents emerge from their use in high doses (often in the treatment of CNS 
infections) or in renal failure.6  Carbapenems more readily penetrate the CNS and their use is associated 
with an increased seizure risk compared with non-carbapenem antibiotics.7 Among the carbapenems, 
imipenem is generally thought to have the highest risk. However, this may be because studies conducted 
on the newer agents (meropenem, ertapenem and doripenem), informed by earlier experience with 
imipenem, generally excluded patients with a history of seizures. Head-to-head comparisons of imipenem 
and meropenem do not reveal significant differences in seizure risk.7  
In addition to their direct effects on the seizure threshold, carbapenems have an interaction with 
valproate which is sufficiently significant to deserve special mention. It is most readily observed with 
meropenem, which is associated with a consistent and substantial reduction in serum valproate 
concentration, in some cases precipitating seizures.8,9 This interaction occurs whether valproate is 
administered enterally or intravenously, and its onset and offset are rapid (within days). Its mechanism is 
uncertain, but its time-course and consistency between routes of administration suggests enhanced 
elimination or redistribution, possibly into red blood cells, as possible candidates.9 
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Isoniazid 
The antituberculous agent isoniazid inhibits pyridoxine phosphokinase, the enzyme which converts 
pyridoxine to its active form, pyridoxal-5-phosphate. Pyridoxal-5-phosphate is an essential cofactor in the 
synthesis of GABA from glutamate. The resulting fall in inhibitory activity and rise in excitatory activity 
leads to a dose-dependent reduction in the seizure threshold. Isoniazid toxicity is characterised by a triad 
of altered mental status, metabolic acidosis and refractory seizures. Treatment with pyridoxine and a 
benzodiazepine usually results in prompt seizure termination. 
Antimalarials 
The antimalarial agents mefloquine and chloroquine can precipitate seizures in people with epilepsy, and 
have also been associated with seizures in healthy individuals.10,11 Depending on resistance patterns, 
doxycycline and atovaquone/proguanil (Malarone®) may be suitable alternatives for malarial prophylaxis 
in patients at risk of seizures. The half-life of doxycycline is reduced in patients taking carbamazepine or 
phenytoin; a higher dosage (100 mg twice daily) should therefore be used.12 
Other antimicrobials 
Fluoroquinolones have comparatively high CNS penetration5 and they may inhibit the GABAA receptor.13 
Seizures are rare but have been reported, particularly with ciprofloxacin in the context of other 
susceptibility factors.6 Macrolides, tetracyclines, aminoglycosides and glycopeptides have not been 
associated with seizures.6 
Analgesics 
Opioid analgesics 
Opioids are associated with diverse effects on the seizure threshold. These vary between drugs, and 
within drugs according to dosage, experimental model and susceptibility factors. For example, morphine 
potentiates chemically-induced seizures but protects against electrically-induced seizures14; the clinical 
implications of this are uncertain. Moreover, the relationships between dosage and seizure threshold are 
complex. Experimentally, morphine has anticonvulsant effects at low doses but is pro-convulsant at high 
doses, whereas this pattern is reversed for fentanyl and pethidine.15 
Tramadol is commonly associated with seizures in overdose,16 and also during therapeutic use. Its 
supplementary effects in inhibiting noradrenaline and serotonin reuptake, not shared by other opioids, 
are often cited as an explanation for this. However, in animal models, tramadol, codeine and morphine 
are similar in their seizure-inducing potential.17,18 Furthermore, increased extracellular concentrations of 
serotonin appear protective against seizures,2 as they may be for antidepressants (see below). These 
findings suggest that the seizure-inducing effects of tramadol are not mediated through the serotonin 
pathway. Rather, they, and presumably those of other opioids, may be due to opioid-dependent 
inhibition of GABAergic pathways18,19 or histamine H1-receptor activation.20 
Non-opioid analgesics 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase enzymes, reducing synthesis of 
prostaglandins from arachidonic acid. The effects of individual prostaglandins vary but, in general, they 
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increase the seizure threshold, and NSAIDs accordingly have potential to lower the seizure threshold.21 
This effect is seen in various models, in a dose-dependent fashion, for aspirin, diclofenac and 
indometacin,21 and there are reports of seizures being caused clinically by these agents during 
therapeutic use.22,23 By contrast, ibuprofen and paracetamol have not been shown to lower the seizure 
threshold and there is some evidence that they may increase it, perhaps because of differential effects on 
individual prostaglandin synthesis.24 Mefenamic acid has a non-linear dose–response effect on seizure 
threhold. In animal models, it suppresses seizures at doses of 20–40 mg/kg,24,25 whereas at 60 mg/kg24 — 
and in toxicity clinically23 — it can induce seizures. 
Methylxantines 
The bronchodilator theophylline, and its soluble derivative aminophylline, cause a significant reduction in 
the seizure threshold in animal models26 and in electroconvulsive therapy.27 The mechanism has been 
ascribed to adenosine A1-receptor antagonism.26 This can lead to seizures in patients with and without 
epilepsy, which can be intractable.28 This may be because methylxanthines also antagonise the actions of 
benzodiazepines.29 Phenytoin is poorly effective and should be avoided. Early use of alternative second-
line agents such as phenobarbital, and if necessary induction of general anaesthesia, is advisable.  
Antipsychotics 
Clozapine has the most marked effects on the seizure threshold, followed by other second-generation 
antipsychotics.30,31 First-generation antipsychotics have only a modest effect. Clozapine is associated with 
concentration-dependent electroencephalographic abnormalities and, in practice, seizures affect 3–6% of 
clozapine-treated patients.32,33 Likewise, seizures are commonly noted in studies of spontaneously 
reported adverse drug reactions,.34 In patients who experience seizures while taking clozapine, the risks 
of discontinuing therapy will often be considered greater than the risks of continuing it. In these 
instances, prophylactic antiepileptic therapy should be offered. Valproate is often a good choice as it is 
well tolerated and has potentially desirable supplementary effects as a mood stabilizer and antimanic 
agent.35 
In contrast to most other antipsychotics, aripiprazole does not lower the seizure threshold during use, 
and may indeed have anticonvulsant properties.30,36 However, a rebound pro-convulsant effect may 
occur on withdrawal.30 
Antidepressants 
The effect of antidepressants on monoaminergic neurotransmission could plausibly modulate the seizure 
threshold in either direction. Clinical trial data suggest that most commonly used antidepressants are 
anticonvulsant.37 Moreover, antidepressant therapy appears to be both safe and beneficial in patients 
with epilepsy and co-morbid depression.38 A recent systematic review reaffirmed this, finding no 
evidence for an increase in seizure frequency in association with the therapeutic use of selective 
serotonin reuptake inhibitors (e.g. citalopram, fluoxetine, sertraline), selective serotonin–noradrenaline 
reuptake inhibitors (e.g. venlafaxine, duloxetine), the selective monoamine oxidase A inhibitor 
moclobemide, or the presynaptic alpha2-adrenoceptor antagonist mirtazapine.39 Among the tricyclic 
antidepressants (TCAs), only clomipramine was associated with a reduction in seizure threshold in 
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therapeutic doses.39 In contrast to the clinical trial data, observational studies using large population 
databases have found an increased risk of seizures in association with most antidepressant drugs.40,41 In a 
recent study of patients not known to have epilepsy,40 the risk of seizures was elevated for all 
antidepressant classes, although low in absolute terms. The conflicting findings from observational and 
interventional studies have several possible explanations, including differences in population 
characteristics, duration, and statistical power. It could also be due to residual confounding in the 
observational studies, arising from the known association between depression and epilepsy.42 Another 
consideration is the potential for different effects at therapeutic versus supra-therapeutic 
concentrations.39 Seizures are common in cases of antidepressant overdose, particularly with venlafaxine 
and TCAs.43 The serotonergic and noradrenergic effects of antidepressants, which predominate at 
therapeutic doses, probably increase the seizure threshold.44 In toxicity, other effects such as inhibition of 
GABAergic and histaminergic transmission may supervene and account for a net reduction in the seizure 
threshold.44 It seems plausible that overdose (intentional or unintentional) may be more common in 
practice than in trials, and captured less completely in observational studies, such that these events could 
account for the excess of seizures observed. 
Bupropion 
The atypical antidepressant bupropion, which inhibits reuptake of noradrenaline and dopamine, is now 
used primarily to aid smoking cessation. It has stimulant effects and a clear dose-dependent relationship 
with seizure risk. Using a prolonged-release preparation in doses licensed for smoking cessation, overt 
seizures are uncommon, affecting approximately 0.1% of patients overall.37 However, the implications of 
a reduction in seizure threshold may be important for individual patients with other susceptibility factors. 
Antiepileptics 
The intended therapeutic effect of antiepileptic drugs is to increase the seizure threshold. However, in 
toxic concentrations, whether through overdose or altered pharmacokinetics, they may paradoxically 
lower it. Furthermore, some forms of epilepsy can be exacerbated by certain antiepileptic agents. For 
example, carbamazepine and, to a lesser extent, gabapentin and lamotrigine may exacerbate idiopathic 
generalised and myoclonic epilepsies.45 Benzodiazepines and barbiturates, which have important roles in 
the management of acute seizures, can similarly induce a paradoxical reduction in seizure threshold 
when taken chronically. Most often, and most predictably, this occurs on withdrawal. Occasionally, 
however, it can occur during introduction or continuation of therapy.45 
Anaesthetics 
The effects of lidocaine on the seizure threshold vary with concentration in a bimodal fashion. At low 
concentrations (0.5–5 mg/L), lidocaine suppresses seizure activity, and indeed is moderately effective as 
a second-line anticonvulsant agent for neonatal seizures.46 However, at concentrations exceeding 8 mg/L 
it lowers the seizure threshold and, with escalating concentrations, will ultimately induces seizures in 
most subjects.47 Lidocaine-induced seizures are generally brief and self-terminating. Bupivicaine can 
similarly reduce the seizure threshold in toxicity, although cardiotoxicity is usually the greater concern in 
these cases. 
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Volatile general anaesthetic agents such as sevoflurane can induce clinical and electroencephalographic 
manifestations of seizure activity at low concentrations, but these are promptly suppressed as the 
concentration increases.48 A similar but less pronounced effect is evident with intravenous agents such as 
propofol and thiopentone which, in higher doses, are a mainstay of treatment for status epilepticus. In 
keeping with this bimodal dose–response pattern, seizures associated with general anaesthesia most 
often occur during induction or emergence, when the concentration of the anaesthetic agent is low.49 
Pre-treatment with a benzodiazepine has been advocated for patients who may be susceptible to these 
transient effects.49 
Conclusion 
Many drugs can adversely affect the seizure threshold, although whether this leads to overt seizures 
depends on the concentration of drug reaching the brain, the susceptibility of the individual to its effects, 
and how these effects vary over time. In managing patients with epilepsy or other risk factors for 
seizures, one must be mindful of the potential for medications to lower the seizure threshold, so as not 
to precipitate avoidable seizures. Likewise, in evaluating patients with seizures, consideration must be 
given to the seizure-provoking potential of their medications. While their contribution may be small in 
comparison to other susceptibility factors, the fact that medicines can be stopped or modified according 
to their risk–benefit balance offers an important route to improving seizure control. 
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Table 1: Drugs that lower the seizure threshold 
Class Examples Notes 
Antimicrobials   
Beta-lactams Penicillins, cephalosporins 
and carbapenems 
In the absence of other susceptibility factors, 
seizures are rare except in high-dose therapy or 
toxic accumulation. 
Antituberculous 
agents 
Isoniazid Seizures are a manifestation of pyridoxal-5-
phosphate  deficiency; they respond to pyridoxine 
and benzodiazepine treatment. 
Antimalarials Mefloquine, chloroquine Doxycycline and atovaquone/proguanil (Malarone®) 
are safer options for malaria prophylaxis in people 
with epilepsy. 
Analgesics   
Opioid Morphine, tramadol, 
codeine, pethidine, 
fentanyl 
Experimental models show inconsistent effects and 
non-linear dose–response relationships. However, 
all opioids appear capable of lowering the seizure 
threshold under certain conditions. 
Non-opioid Aspirin, diclofenac, 
indomethacin 
Paracetamol and ibuprofen do not appear to lower 
the seizure threshold. Mefenamic acid has a non-
linear dose–response effect on the seizure 
threshold; it is pro-convulsant in toxicity. 
Methylxanthines Theophylline, 
aminophylline 
Thought to be due adenosine A1-receptor 
antagonism. Benzodiazepines may be poorly 
effective; phenytoin is generally ineffective. 
Antipsychotics Clozapine and, to a lesser 
extent, other 
antipsychotics (e.g. 
risperidone, olanzapine) 
Where clozapine is the only effective option, it may 
be appropriate to continue it together with an 
antiepileptic agent (e.g. valproate).  
Antidepressants Bupropion 
Other antidepressants, 
particularly tricyclics, in 
overdose 
Bupropion (used in smoking cessation) is clearly 
associated with seizures. Data for other 
antidepressants at therapeutic dose are conflicting, 
but seizures are a common feature of toxicity. 
Antiepileptics Carbamazepine 
Benzodiazepines (e.g. 
diazepam) on withdrawal 
of chronic therapy 
Most antiepileptics can induce paradoxical seizures 
in overdose. Also, carbamazepine can exacerbate 
certain primarily generalised seizure types. 
Withdrawal from benzodiazepines invariably lowers 
the seizure threshold. 
Anaesthetics Sevoflurane Volatile and intravenous anaesthetics invariably 
suppress seizures at therapeutic doses, but may 
transiently lower the seizure threshold at sub-
therapeutic doses. 
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